Last reviewed · How we verify
glioblastoma multiforme multipeptide vaccine IMA950
glioblastoma multiforme multipeptide vaccine IMA950 is a Biologic drug developed by Cancer Research UK. It is currently in Phase 1 development.
At a glance
| Generic name | glioblastoma multiforme multipeptide vaccine IMA950 |
|---|---|
| Sponsor | Cancer Research UK |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma (PHASE1, PHASE2)
- A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) (PHASE1)
- Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma (PHASE1, PHASE2)
- Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE1)
- Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glioblastoma multiforme multipeptide vaccine IMA950 CI brief — competitive landscape report
- glioblastoma multiforme multipeptide vaccine IMA950 updates RSS · CI watch RSS
- Cancer Research UK portfolio CI
Frequently asked questions about glioblastoma multiforme multipeptide vaccine IMA950
What is glioblastoma multiforme multipeptide vaccine IMA950?
glioblastoma multiforme multipeptide vaccine IMA950 is a Biologic drug developed by Cancer Research UK.
Who makes glioblastoma multiforme multipeptide vaccine IMA950?
glioblastoma multiforme multipeptide vaccine IMA950 is developed by Cancer Research UK (see full Cancer Research UK pipeline at /company/cancer-research-uk).
What development phase is glioblastoma multiforme multipeptide vaccine IMA950 in?
glioblastoma multiforme multipeptide vaccine IMA950 is in Phase 1.